DK1132403T3 - TGF G Beta1-inhibitorpeptider - Google Patents

TGF G Beta1-inhibitorpeptider

Info

Publication number
DK1132403T3
DK1132403T3 DK99957342T DK99957342T DK1132403T3 DK 1132403 T3 DK1132403 T3 DK 1132403T3 DK 99957342 T DK99957342 T DK 99957342T DK 99957342 T DK99957342 T DK 99957342T DK 1132403 T3 DK1132403 T3 DK 1132403T3
Authority
DK
Denmark
Prior art keywords
tgf
inhibitor peptides
compositions
manufacture
beta1
Prior art date
Application number
DK99957342T
Other languages
Danish (da)
English (en)
Inventor
Sagastibelza Juan Jose Lasarte
Valtuena Jesus Prieto
Saenz Ignacio Jose Ezquerro
Cuesta Francisco Borras
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Application granted granted Critical
Publication of DK1132403T3 publication Critical patent/DK1132403T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK99957342T 1998-11-24 1999-11-23 TGF G Beta1-inhibitorpeptider DK1132403T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009802465A ES2146552B1 (es) 1998-11-24 1998-11-24 Peptidos inhibidores de tgf/31

Publications (1)

Publication Number Publication Date
DK1132403T3 true DK1132403T3 (da) 2006-08-14

Family

ID=8305903

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99957342T DK1132403T3 (da) 1998-11-24 1999-11-23 TGF G Beta1-inhibitorpeptider

Country Status (16)

Country Link
US (2) US7057013B1 (es)
EP (1) EP1132403B1 (es)
JP (5) JP3836677B2 (es)
CN (1) CN1203091C (es)
AT (1) ATE322505T1 (es)
AU (1) AU767498B2 (es)
BR (1) BR9915604B1 (es)
CA (1) CA2352537C (es)
CY (1) CY1105616T1 (es)
DE (1) DE69930763T2 (es)
DK (1) DK1132403T3 (es)
ES (2) ES2146552B1 (es)
PT (1) PT1132403E (es)
RU (1) RU2232771C2 (es)
SI (1) SI1132403T1 (es)
WO (1) WO2000031135A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723473B2 (en) * 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
JP2002087938A (ja) * 2000-09-11 2002-03-27 Shiseido Co Ltd 養毛剤及びそのスクリーニング方法
WO2003093293A2 (en) * 2002-04-29 2003-11-13 Saint Louis University Peptide antagonists of tgf-beta family members and therapeutic uses thereof
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US20090263410A1 (en) * 2005-10-24 2009-10-22 Proyecto De Biomedicina Cima, S.L. Use of tgf-b1 inhibitor peptides in the preparation of an immune response modulating agent
US7582609B2 (en) * 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
KR100879239B1 (ko) * 2007-04-19 2009-01-16 (주)케어젠 Ｔｇｆｐ－ｃａｐ 펩타이드 및 그의 용도
ES2327088B1 (es) * 2007-08-20 2010-07-26 Proyecto De Biomedicina Cima S.L. Combinaciones terapeuticas para el tratamiento de las metastasis.
EP2192904B1 (en) 2007-08-27 2016-08-17 Auxagen, Inc. METHODS FOR INHIBITING TGF-beta
JP4630914B2 (ja) 2008-04-14 2011-02-09 株式会社日本ハイポックス 肝線維化抑制剤
US20110293557A1 (en) 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
EP2341913B1 (en) * 2008-09-16 2014-11-19 Saint Louis University Method of enhancing tgf-beta signalling
CA2750559A1 (en) * 2009-02-05 2010-08-12 Digna Biotech, S.L. Pharmaceutical formulations of tgf-.beta.1 inhibitor peptides
ES2347627B1 (es) 2009-03-06 2011-10-10 Isdin, S.A. Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales.
KR100983182B1 (ko) * 2009-08-14 2010-09-20 (주)엔솔테크 신규 펩타이드 및 그 용도
CN102712933A (zh) 2009-11-05 2012-10-03 西马生物医学计划公司 调控的表达系统
EP4219560A3 (en) * 2010-02-18 2023-08-23 The Regents of The University of California Integrin alpha v beta 8 neutralizing antibody
CN102898508B (zh) * 2011-08-12 2014-04-30 北京大学第一医院 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
US9562912B2 (en) 2011-09-05 2017-02-07 Pola Pharma Inc. Method of identifying abnormal cells by expression levels of ETFB
CU24181B1 (es) * 2012-11-09 2016-04-25 Ct De Inmunología Molecular POLIPÉPTIDOS DERIVADOS DEL TGFß
HUE049377T2 (hu) 2013-03-14 2020-09-28 Brigham & Womens Hospital Inc Készítmények és eljárások epiteliális õssejtek expanziójára és tenyésztésére
RU2016106641A (ru) 2013-07-30 2017-09-01 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтические средства, направленные на ecm эндотелия роговицы
US20150056199A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
EP3064222B1 (en) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
EP3071215B1 (en) 2013-11-21 2020-01-08 The Brigham and Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
EP3693004A1 (en) * 2014-08-01 2020-08-12 The Brigham and Women's Hospital, Inc. An inhibitor of gdf-15 for use in treating fibrosis
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
KR20180035884A (ko) 2015-08-04 2018-04-06 악셀레론 파마 인코포레이티드 골수증식성 장애를 치료하기 위한 방법
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
KR101841748B1 (ko) 2016-02-18 2018-05-08 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
KR101791526B1 (ko) * 2016-02-18 2017-11-01 (주)케어젠 발모 촉진 활성을 나타내는 펩타이드 및 이의 용도
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
AU2017235461B2 (en) 2016-03-15 2023-02-23 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2018204594A1 (en) 2017-05-04 2018-11-08 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
KR101954214B1 (ko) * 2017-05-23 2019-03-06 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
US11866427B2 (en) 2018-03-20 2024-01-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
CN109432431B (zh) 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
KR102265432B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
CN110511285B (zh) * 2019-08-27 2023-01-24 南京安吉生物科技有限公司 一种重组融合多肽及其应用
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
JP2023549894A (ja) * 2020-12-23 2023-11-29 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ＴＧＦ－βシグナル伝達を抑制できる新規なペプチドおよびその用途
KR20240000395A (ko) * 2022-06-22 2024-01-02 주식회사 유씨아이테라퓨틱스 TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
JPH06500574A (ja) * 1991-05-10 1994-01-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
FR2720069A1 (fr) * 1994-05-19 1995-11-24 Inst Nat Sante Rech Med Dérivés de facteurs de croissance et d'hormones de la superfamille des TGFB, procédé pour leur obtention et leurs applications biologiques.
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy

Also Published As

Publication number Publication date
BR9915604A (pt) 2001-08-07
CY1105616T1 (el) 2010-07-28
PT1132403E (pt) 2006-07-31
EP1132403B1 (en) 2006-04-05
CN1203091C (zh) 2005-05-25
BR9915604B1 (pt) 2011-07-26
AU767498B2 (en) 2003-11-13
ES2262349T3 (es) 2006-11-16
EP1132403A1 (en) 2001-09-12
JP2002530431A (ja) 2002-09-17
DE69930763D1 (en) 2006-05-18
RU2232771C2 (ru) 2004-07-20
AU1507700A (en) 2000-06-13
JP2007186519A (ja) 2007-07-26
CN1328569A (zh) 2001-12-26
DE69930763T2 (de) 2006-11-30
JP2006241166A (ja) 2006-09-14
JP4068654B2 (ja) 2008-03-26
ES2146552B1 (es) 2001-04-16
WO2000031135A1 (es) 2000-06-02
JP4237807B2 (ja) 2009-03-11
US20070014767A1 (en) 2007-01-18
ATE322505T1 (de) 2006-04-15
CA2352537C (en) 2011-11-15
CA2352537A1 (en) 2000-06-02
US7057013B1 (en) 2006-06-06
JP4002287B2 (ja) 2007-10-31
JP3836677B2 (ja) 2006-10-25
JP2008056685A (ja) 2008-03-13
ES2146552A1 (es) 2000-08-01
JP4272255B2 (ja) 2009-06-03
US7528226B2 (en) 2009-05-05
SI1132403T1 (sl) 2006-08-31
JP2009040796A (ja) 2009-02-26

Similar Documents

Publication Publication Date Title
DK1132403T3 (da) TGF G Beta1-inhibitorpeptider
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
DE69938174D1 (de) Peptid zusammensetzungen und formulierungen unter verwendung derselben
EE9800306A (et) Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad
ATE253063T1 (de) 5-ht1f-agonisten
ID26819A (id) Turunan imidazo piridina yang menghambat sekresi asam lambung
DE60115602D1 (de) Verwendung von säurestabilen subtilisinproteasen in tierfutter
GB9806632D0 (en) Peptide factor
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ATE500328T1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
CA2123315A1 (en) Therapeutic agents which are antagonists or partial agonists of human interleukin 4
BR0207039A (pt) Polipeptìdeos de fusão da glicoproteìna ib alfa plaquetária e seus métodos de uso
DE68907635D1 (de) Loetmaterial fuer brillengestelle und brillengestelle, bei denen dieses loetmaterial verwendet ist.
ITMI920955A1 (it) Idrogeli di tipo polietereammidoamminico come materiali eparinizzabili
NO20002408D0 (no) 5-HT1F antagonister
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
ATE282609T1 (de) Neue substituierte n-methyl-n-(4-(4-(1h- benzimidazol-2-yl) (1,4)diazepan-1-yl)-2- (aryl)butyl)benzamide zur behandlung von allergischen krankheiten
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
DE69719190D1 (de) Kolostrum enthaltende pharmazeutische zusammensetzungen und deren verwendung
ITRM920516A0 (it) Composizione e suo uso per il trattamento terapeutico di affezioni dermatitiche, particolarmente la psoriasi.
ZA971321B (en) Novel substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl)[1,4]diazepan-1-yl)-2-(aryl)butyl)benzamide useful for the treatment of allergic diseases.
IT240435Y1 (it) Accessorio per il prolungamento di stecche da biliardo o simili,ad elevata praticita' di impiego